189 related articles for article (PubMed ID: 32383192)
21. Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K; Tan J; Wu T
Cochrane Database Syst Rev; 2009 Jan; (1):CD006719. PubMed ID: 19160296
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Parrondo RD; Dutta N; LaPlant BR; Elliott J; Fernandez A; Zimmerman A; Cicco G; Han B; Heslop K; Chapin D; Sher T; Roy V; Rasheed A; Das S; Chanan-Khan AA; Paulus A; Ailawadhi S
Br J Haematol; 2024 May; 204(5):1825-1829. PubMed ID: 38286472
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
Treon SP; Hanzis C; Tripsas C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):133-5. PubMed ID: 21454214
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
Tamburini J; Lévy V; Chaleteix C; Fermand JP; Delmer A; Stalniewicz L; Morel P; Dreyfus F; Grange MJ; Christian B; Choquet S; Leblond V
Leukemia; 2005 Oct; 19(10):1831-4. PubMed ID: 16121217
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158
[No Abstract] [Full Text] [Related]
27. [Diffuse large cell lymphoma and colon adenocarcinoma in patient with Waldenström's macroglobulinaemia].
Radojković M; Ristić S; Colović N; Cemerikić-Martinović V; Colović M
Srp Arh Celok Lek; 2011; 139(1-2):95-8. PubMed ID: 21568089
[TBL] [Abstract][Full Text] [Related]
28. Circulating low CD4
Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
[TBL] [Abstract][Full Text] [Related]
29. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
30. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Tedeschi A; Ricci F; Goldaniga MC; Benevolo G; Varettoni M; Motta M; Pioltelli P; Gini G; Barate' C; Luraschi A; Vismara E; Frustaci AM; Nichelatti M; Vitolo U; Baldini L; Morra E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):231-4. PubMed ID: 23490992
[TBL] [Abstract][Full Text] [Related]
31. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
32. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
33. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
34. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
35. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig WD; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
Leukemia; 2009 Jan; 23(1):153-61. PubMed ID: 18818699
[TBL] [Abstract][Full Text] [Related]
36. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
37. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
38. Waldenström's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients.
Petrucci MT; Avvisati G; Tribalto M; Giovangrossi P; Mandelli F
J Intern Med; 1989 Dec; 226(6):443-7. PubMed ID: 2518735
[TBL] [Abstract][Full Text] [Related]
39. Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia.
Vos JM; Minnema MC; Wijermans PW; Croockewit S; Chamuleau ME; Pals ST; Klein SK; Delforge M; van Imhoff GW; Kersten MJ; ;
Neth J Med; 2013 Mar; 71(2):54-62. PubMed ID: 23462052
[TBL] [Abstract][Full Text] [Related]
40. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
